Hanmi R&D becomes stronger through cooperation with partners.
- efocipegtrutide (LAPSTriple agonist)
- sonefpeglutide (LAPSGLP-2 analog)
- efpegerglucagon (LAPSGlucagon analog)
- HM97662 (EZH1/2 inhibitor)
- BH3120 (PD-L1/4-1BB BsAb)
- HM15275 (LA-GLP/GIP/GCG)
- HM16390 (LAPSIL-2 analog)
- HM17321 (LA-UCN2)
- HM99462 (SOS1 inhibitor)
- LAPS Glucagon Combo
efpegerglucagon (LAPSGlucagon analog)
Rare Disease
Phase 2
Overview
Proven concept for sustained glucose elevation novel option
for preventive treatment of CHI
Description
for preventive treatment of CHI
Efpegerglucagon is a long-acting glucagon analog chemically conjugated with constant region of human immunoglobulin via non-peptidyl flexible linker.
The main physiological effects of glucagon receptor agonism (increasing glycogenolysis and gluconeogenesis) and favorable physicochemical and PK properties suggest therapeutic potential of Efpegerglucagon in subjects with chronic hypoglycemic diseases such as congenital hyperinsulinism (CHI) and hypoglycemia post-bariatric surgery (PBH). Efpegerglucagon received orphan drug designation from the FDA, EMA, and MFDS for the treatment of CHI, and received rare pediatric disease designation from in the U.S FDA. Efpegerglucagon has also been designated as an orphan drug by the EMA for the treatment of insulin autoimmune syndrome.
Additionally, glucagon receptor agonism is also associated with increased energy expenditure and improvement of various cardiometabolic risk factors. In nonclinical studies, improved lipid profile, kidney function, and blood pressure were observed along with a remarkable weight loss effect.
The main physiological effects of glucagon receptor agonism (increasing glycogenolysis and gluconeogenesis) and favorable physicochemical and PK properties suggest therapeutic potential of Efpegerglucagon in subjects with chronic hypoglycemic diseases such as congenital hyperinsulinism (CHI) and hypoglycemia post-bariatric surgery (PBH). Efpegerglucagon received orphan drug designation from the FDA, EMA, and MFDS for the treatment of CHI, and received rare pediatric disease designation from in the U.S FDA. Efpegerglucagon has also been designated as an orphan drug by the EMA for the treatment of insulin autoimmune syndrome.
Additionally, glucagon receptor agonism is also associated with increased energy expenditure and improvement of various cardiometabolic risk factors. In nonclinical studies, improved lipid profile, kidney function, and blood pressure were observed along with a remarkable weight loss effect.
Glucagon receptor agonism (for chronichypoglycemic disease)
- Sustained glycogenolysis
- Sustained gluconeogenesis
- Body weight loss via food intake inhibition, increased energy expenditure, and lipid metabolism
- Improved insulin resistance through weight loss (lipid profile)
- Extended duration of action by LAPSCOVERY
- Targeting first-in-class weekly glucagon agonist
Clinical Development
- A phase 1a and 1b study were completed NCT04032782 NCT04167553
- A phase 2a study is currently ongoing with CHI patients in US, UK, Germany and Israel. NCT04732416
Publications